Haleon plc has completed the acquisition of the remaining 12% stake in its joint venture in China, Tianjin TSKF Pharmaceutical Co. Ltd, for RMB 1,623 million on June 27, 2025, making it a wholly owned subsidiary, which significantly contributes to its revenues in a key market.